Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data

January 2012
Cardiovascular Diabetology;2012, Vol. 11 Issue 1, p6
Academic Journal
The article presents a research which examines the efficacy of cardiovascular (CV) safety of the selective dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin for the treatment of type 2 diabetes mellitus (T2DM). It is reported that, the researchers carried out a retrospective meta-analysis to conduct the research.


Related Articles

  • Case Study--Managing newly diagnosed type-2 diabetes. Bostock-Cox, Beverley // Independent Nurse;6/4/2010, p1 

    The article presents a case study of a 58-year old man, Charlie, who underwent an axillary abscess and was diagnosed as a possible candidate for diabetes. Several changes in his lifestyle and dietary habits for reducing risks of cardiovascular diseases and a continuous monitoring routine were...

  • Meeting glycemic goals: Options beyond metformin. DeBenederte, Valerie // Drug Topics;Nov2012 Supplement, p8s 

    The article discusses the options in drug treatment for type 2 diabetes patients beyond the use of metformin in controlling glycemic and glycosylated hemoglobin (HbA1c) levels. Clinical professor Stefanie C. Nigro explains that approaches in diabetes management and patient care plan may differ...

  • The Clinical Investigation of Securigera Securidaca (l.) Degen & Doerfler Seeds in Treatment of Type II Diabetic Patients: A Randomized, Double - Blind, Placebo - Controlled Study. Larijani, Bagher // Diabetes;Jun2007 Supplement 1, Vol. 56, pA562 

    Backgrounds and Aims: Securigera securidaca (L.) seeds is used by traditional herbalists for the treatment of diabetes in several parts of Iran. Clinical investigation of its efficacy and its toxicity in diabetic patients is of importance. Methods: A 2 - month randomized double blind clinical...

  • Comparison of Glucose Lowering Effect of Metformin and Acarbose in Type 2 Diabetes Mellitus: A Meta-Analysis. Gu, Shuyan; Shi, Jihao; Tang, Zhiliu; Sawhney, Monika; Hu, Huimei; Shi, Lizheng; Fonseca, Vivian; Dong, Hengjin // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Background: Metformin is the first-line oral hypoglycemic agent for type 2 diabetes mellitus recommended by international guidelines. However, little information exists comparing it with acarbose which is also commonly used in China. This study expanded knowledge by combining direct and...

  • Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.  // Cardiovascular Diabetology;2012, Vol. 11 Issue 1, p3 

    The article presents a research which examines the efficacy of cardiovascular (CV) safety profile of the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin compared to comparator treatments in patients with type 2 diabetes mellitus (T2DM). It is reported that, the researchers used methods like,...

  • The pluses and minuses of ADDITION-Europe. Sattar, Naveed // Diabetes Digest;2011, Vol. 10 Issue 4, p205 

    The article offers information on the results of the Anglo-Danish-Dutch Study of Intensive Treatment in People With Screen Detected Diabetes in Primary Care (ADDITION)-Europe. It says that the study has been considered as negative due to the lesser efficacy of intensive treatment as compared to...

  • Psychoeducative groups help control type 2 diabetes in a primary care setting. Cuesta, Miguel Ángel Cervantes; Espín, Noelia Victoria García-Talavera; Román, Josefa Brotons; Sánchez, M. Ángeles Núñez; Ibáñez, Pedro Brocal; Martín, Pilar Villalba; García, Carmen Saura; Esteban, Tomasa Sánchez; López-Reinoso, Helena Romero; Aroca, Ma. José Delgado; Gil, Dolores Sánchez; Aviles, Amparo Meoro; Palao, José Soriano // Nutricion Hospitalaria;mar/abr2013, Vol. 28 Issue 2, p497 

    Introduction: The purpose of this study is to measure the impact of a psychoeducational group intervention in diabetes using glycosylated haemoglobin (HbAlc), the body mass index (BMI) and cardiovascular risk factors (CVRF) compared with conventional educational measures provided individually....

  • A Retrospective Medication Use Evaluation of Pioglitazone in Patients With Type 2 Diabetes Mellitus in a County Health Care System. John, Ligy; Milton-Brown, Jacqueline; Lal, Lincy S. // Hospital Pharmacy;Jan2008, Vol. 43 Issue 1, p35 

    Background: Pioglitazone is a thiazolidinedione oral second-line antihyperglycemic agent in the treatment of type 2 diabetes but was the highest expenditure within restricted drugs in this county health care system. Objective: A medication use evaluation of pioglitazone was conducted to...

  • Effect of a Low-Glycemic Index or a High-Cereal Fiber Diet on Type 2 Diabetes. Jenkins, David J. A.; Kendall, Cyril W. C .; McKeown-Eyssen, Gail; Josse, Robert G.; Silverberg, Jay; Booth, Gillian L.; Vidgen, Edward; Josse, Andrea R.; Nguyen, Tri H.; Corrigan, Sorcha; Banach, Monica S.; Ares, Sophie; Mitchell, Sandy; Emam, Azadeh; Augustin, Livia S. A.; Parker, Tina L.; Leiter, Lawrence A, // JAMA: Journal of the American Medical Association;12/17/2008, Vol. 300 Issue 23, p2742 

    The article presents a randomized parallel study which tested the effects of low-glycemic index diets on cardiovascular risk factors and glycemic control in patients with type two diabetes. 210 participants with type two diabetes who were treated with antihyperglycemic medications were randomly...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics